Shanghai Haohai Biological Tech Co (688366) - Total Assets
Based on the latest financial reports, Shanghai Haohai Biological Tech Co (688366) holds total assets worth CN¥7.12 Billion CNY (≈ $1.04 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Shanghai Haohai Biological Tech Co reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Shanghai Haohai Biological Tech Co - Total Assets Trend (2012–2024)
This chart illustrates how Shanghai Haohai Biological Tech Co's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Shanghai Haohai Biological Tech Co to evaluate the quality of earnings relative to operating cash generation.
Shanghai Haohai Biological Tech Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Haohai Biological Tech Co's total assets of CN¥7.12 Billion consist of 51.4% current assets and 48.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 36.9% |
| Accounts Receivable | CN¥369.34 Million | 5.2% |
| Inventory | CN¥490.65 Million | 6.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥705.10 Million | 9.9% |
| Goodwill | CN¥422.93 Million | 5.9% |
Asset Composition Trend (2012–2024)
This chart illustrates how Shanghai Haohai Biological Tech Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688366 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Haohai Biological Tech Co's current assets represent 51.4% of total assets in 2024, a decrease from 54.8% in 2012.
- Cash Position: Cash and equivalents constituted 36.9% of total assets in 2024, up from 35.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 9.9% of total assets.
Shanghai Haohai Biological Tech Co Competitors by Total Assets
Key competitors of Shanghai Haohai Biological Tech Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Shanghai Haohai Biological Tech Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.77 | 4.30 | 8.78 |
| Quick Ratio | 3.24 | 3.71 | 8.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.66 Billion | CN¥2.84 Billion | CN¥3.38 Billion |
Shanghai Haohai Biological Tech Co - Advanced Valuation Insights
This section examines the relationship between Shanghai Haohai Biological Tech Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.85 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | CN¥7.12 Billion |
| Market Capitalization | $839.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Haohai Biological Tech Co's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shanghai Haohai Biological Tech Co's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shanghai Haohai Biological Tech Co (2012–2024)
The table below shows the annual total assets of Shanghai Haohai Biological Tech Co from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.12 Billion ≈ $1.04 Billion |
+0.22% |
| 2023-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+3.09% |
| 2022-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
-0.83% |
| 2021-12-31 | CN¥6.95 Billion ≈ $1.02 Billion |
+10.35% |
| 2020-12-31 | CN¥6.30 Billion ≈ $921.70 Million |
+2.39% |
| 2019-12-31 | CN¥6.15 Billion ≈ $900.21 Million |
+38.67% |
| 2018-12-31 | CN¥4.44 Billion ≈ $649.18 Million |
+8.86% |
| 2017-12-31 | CN¥4.08 Billion ≈ $596.34 Million |
+10.34% |
| 2016-12-31 | CN¥3.69 Billion ≈ $540.46 Million |
+30.88% |
| 2015-12-31 | CN¥2.82 Billion ≈ $412.93 Million |
+275.30% |
| 2014-12-31 | CN¥751.90 Million ≈ $110.03 Million |
+21.04% |
| 2013-12-31 | CN¥621.18 Million ≈ $90.90 Million |
+38.64% |
| 2012-12-31 | CN¥448.04 Million ≈ $65.56 Million |
-- |
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more